Related Experiment Video
Updated: May 30, 2026
Scoring Central Nervous System Inflammation, Demyelination, and Axon Injury in Experimental Autoimmune Encephalomyelitis
Published on: February 23, 2024
Serum and CSF PDGF-AA and FGF-2 in relapsing-remitting multiple sclerosis: a case-control study
M H Harirchian1, A H Tekieh, A Modabbernia
1Department of Neurology, Imam Khomeini Hospital, Iranian Centre of Neurological Research, Tehran University of Medical Sciences, Tehran, Iran.
Background And Purpose:
Fibroblast growth factor-2 (FGF-2) and platelet-derived growth factor-A (PDGF-AA) are potent modulators of oligodendrocytes, the main responsible cells for myelin regeneration. We measured FGF-2 and PDGF-AA in the sera and cerebrospinal fluid (CSF) of patients with relapsing-remitting multiple sclerosis (RR-MS) and compared these values with control subjects.
Methods:
Twenty-three patients with RR-MS and 23 subjects without inflammatory and demyelinating diseases were included. Serum samples of the patients were collected in both relapse and remission phases and were analyzed with ELISA method. CSF was drawn during the relapse period. Blood and CSF were drawn from control subjects for comparison. Wilcoxon and Mann-Whitney U-test and Spearman's rank correlation were used for analysis. P values of <0.05 were considered significant.
Results:
Age and sex distribution were similar in both groups. Serum values of FGF-2 were higher in relapse phase compared with remission phase, with a trend toward significance (P=0.052). CSF PDGF-AA showed significant negative correlation with disease duration (correlation coefficient=-0.58, P=0.004). Serum levels of PDGF did not differ between two phases significantly. There was no difference in serum and CSF values of these factors between patients and controls. When we compared patients with prolonged disease with controls, a significant difference between the CSF levels of PDGF-AA was observed (mean±SEM 2.78±0.8 in controls vs. 0.55±0.29 in patients with MS≥2 years, P<0.05).
Conclusion:
Our study was the first to show that CSF PDGF-AA is related to disease duration. Supporting previous findings we showed that serum and CSF levels of these factors are weak indicators of disease severity.
Insights
Platelet-derived growth factor-A (PDGF-AA) in cerebrospinal fluid (CSF) correlates with multiple sclerosis (MS) duration. Serum and CSF levels of FGF-2 and PDGF-AA are not strong indicators of MS disease severity.
Area of Science:
- Neuroscience
- Immunology
- Biochemistry
Background:
- Oligodendrocytes are crucial for myelin regeneration in multiple sclerosis (MS).
- Fibroblast growth factor-2 (FGF-2) and platelet-derived growth factor-A (PDGF-AA) influence oligodendrocyte function.
- Understanding the role of these growth factors in MS pathogenesis is essential.
Purpose of the Study:
- To measure serum and cerebrospinal fluid (CSF) levels of FGF-2 and PDGF-AA in patients with relapsing-remitting multiple sclerosis (RR-MS).
- To compare these levels with those in control subjects.
- To investigate the correlation of these factors with disease duration and severity.
Main Methods:
- Serum and CSF samples were collected from 23 RR-MS patients during relapse and remission phases, and from 23 controls.
- Enzyme-linked immunosorbent assay (ELISA) was used to quantify FGF-2 and PDGF-AA.
- Statistical analyses included Wilcoxon, Mann-Whitney U-test, and Spearman's rank correlation.
Main Results:
- Serum FGF-2 showed a trend towards higher levels during MS relapse (P=0.052).
- CSF PDGF-AA significantly negatively correlated with disease duration (r=-0.58, P=0.004).
- CSF PDGF-AA levels were significantly lower in patients with MS duration ≥2 years compared to controls (P<0.05).
Conclusions:
- CSF PDGF-AA is associated with the duration of multiple sclerosis.
- Serum and CSF levels of FGF-2 and PDGF-AA appear to be weak indicators of MS disease severity.
